Inhibition of c-Myc suppresses proliferation and induces differentiation in primary AML cells.

<p>(A) BMMCs were collected from AML patients, which contained 5 refractory and relapsed (R) AML patients and 4 newly diagnosed (N) AML patients. Real time-PCR analysis was performed to clarify the mRNA expression of <i>c-Myc</i> (a) and <i>C/EBPβ</i> (b). The relative expression values from different patients were presented in a box plot graph. The horizontal line within each box represented the median value. The correlation between <i>c-Myc</i> and <i>C/EBPβ</i> expression was shown as (c). (B) BMMCs from five newly diagnosed AML patients were treated with 100 µM 10058-F4 for 48 h. The CD11b-positive cells was analyzed by flow cytometry (a), and the percentages of CD11b expression were under census (n = 5; b). (C) The anti-proliferation of 10058-F4 to BMMCs was detected by MTT assay. (D) The expression of <i>c-Myc</i> and <i>C/EBPβ</i> in BMMCs treated with 10058-F4 was detected by Real-time PCR. *p<0.05, **p<0.01, ***p<0.001, Student's t test.